Asthma is a chronic heterogenous disease, airway eosinophilic inflammation can be reduced with biologics; however, there remains many unmet needs in the treatment of type-2 low severe asthma. It was a pleasure to talk with our editorial board member, Prof. Antonio Spanevello (University of Insubria and Maugeri Care and Research Institute, IRCCS Tradate, Varese, Italy) to learn more around the latest updates in asthma treatment, including the phase 2 and 3 trials surrounding risankizumab and tezepelumab in severe asthma and the most promising targets under investigation.
‘Biologics in non eosinophilic asthma’ was presented at CHEST Congress 2022, 27-29 June 2022.
- Why do you think that risankizumab failed to show a clinical benefit in patients with severe asthma, and what does this mean for current and future research targeting cytokines? (0:29)
- Could you tell us a little about tezepelumab and the findings of the NAVIGATOR and PATHWAY clinical trials? (2:21)
- Which emerging molecular targets do you consider promising? (3:52)
Disclosures: Antonio Spanevello discloses consulting for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; receiving grant/ research support from GSK and Chiesi; serving on advisory boards for GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini; and receiving honoraria from GSK, Chiesi, MSD, Astrazeneca, Sanofi and Menarini.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
Share this Video
Related Videos In Asthma
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
Treatment strategies for metabolic perturbations in obesity-related asthma: Anne E. Dixon, ATS 2023
Recent epidemiological studies have shown that treatments for obesity-mediated metabolic perturbations such as GLP-1 receptors might improve symptoms in obesity-related asthma. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the treatment strategies associated with obesity-mediated metabolic perturbations, the data surrounding weight loss as […]
Diagnosis, management and pathophysiology of obesity-related asthma: Anne E. Dixon, ATS 2023
Obesity-related asthma is associated with poorer control and a greater number of exacerbations of asthma, which in turn reduces patient quality-of-life. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the difficulties in the diagnosis and management of obese asthma, the association between […]